Clinical outcomes in ER+ HER2 -node-positive breast cancer patients who were treated according to the Recurrence Score results: evidence from a large prospectively designed registrySalomon M. Stemmer, Noa Ben-Baruch, Georgeta Fried et al.|npj Breast Cancer|2017Cited by 87
Clinical outcomes in patients with node-negative breast cancer treated based on the recurrence score results: evidence from a large prospectively designed registrySalomon M. Stemmer, Nicky Liebermann, Mariana Steiner et al.|npj Breast Cancer|2017Cited by 70
Clinical outcomes in ER+ HER2-negative breast cancer (BC) where treatment decisions incorporated the 21-gene recurrence score (RS): Elderly (≥70 yrs) vs younger patients (Pts).Salomon M. Stemmer, David Geffen, Mariana Steiner et al.|Journal of Clinical Oncology|2017Cited by 0
Treatments/clinical outcomes in ER+ HER2-negative breast cancer (BC) where treatment decisions were recurrence score (RS)-guided: Analysis by histologic subtype.Salomon M. Stemmer, Nicky Liebermann, Mariana Steiner et al.|Journal of Clinical Oncology|2017Cited by 0
Abstract P1-07-14: Real-life analysis evaluating >1000 N0/N1mi estrogen receptor (ER)+ breast cancer patients for whom treatment decisions incorporated the 21-gene recurrence score (RS) result: Clinical outcomes with median follow up of > 9 yearsSalomon M. Stemmer, N Ben Baruch, Shulamith Rizel et al.|Cancer Research|2018Cited by 0